title: The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
abstract: OBJECTIVE
  To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia.
  
  
  METHODS
  Fifty-two patients were investigated for the three-month effect of 200 mg per day micronised fenofibrate on the serum enzyme activity and concentration of PON and their relationship with serum lipids, high-density lipoprotein (HDL-C) parameters.
  
  
  RESULTS
  Serum paraoxonase activity was lower in CHD patients with type IIb hyperlipoproteinemia. During the three-month study it was observed that following treatment with micronised fenofibrate, serum triglyceride and cholesterol levels decreased, while HDL-C increased significantly (p<0.001). Low-density lipoprotein (p<0.05) and apolipoprotein B-100 (p<0.01) decreased, while HDL constituent apolipoprotein A-I (p<0.05) increased after micronised fenofibrate treatment. The HDL-associated paraoxonase specific activity increased significantly (p<0.05). To assess whether the increased PON activity was due to elevated HDL and apoA-I level, we standardized PON activity for HDL and apoA-I concentrations. The standardized values for HDL (PON/HDL) increased (p<0.05) while the PON/apoA-I ratio did not change significantly.
  
  
  CONCLUSIONS
  Three months of treatment with micronised fenofibrate is thought to normalize lipid profile and improve antioxidant status by increasing serum paraoxonase activity in these patients.
authors.affiliation: 1st Department of Medicine, University of Debrecen, Medical and Health Science Center, Nagyerdei krt. 98, H-4012 Debrecen, Hungary. paragh@ibel.dote.hu
authors.forename: G
authors.initials: G
authors.lastname: Paragh
authors.forename: I
authors.initials: I
authors.lastname: Seres
authors.forename: M
authors.initials: M
authors.lastname: Harangi
authors.forename: Z
authors.initials: Z
authors.lastname: Balogh
authors.forename: L
authors.initials: L
authors.lastname: Illyés
authors.forename: J
authors.initials: J
authors.lastname: Boda
authors.forename: Z
authors.initials: Z
authors.lastname: Szilvássy
authors.forename: P
authors.initials: P
authors.lastname: Kovács
mesh_terms: D000328:Adult; D000975:Antioxidants; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D043303:Aryldialkylphosphatase / Q000097:blood*; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000201:enzymology*; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D014280:Triglycerides / Q000097:blood
chemical_list: D000975:Antioxidants; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D043303:Aryldialkylphosphatase; D011345:Fenofibrate